This company has been marked as potentially delisted and may not be actively trading. Genesis Healthcare (GEN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipTrendsBuy This Stock GEN vs. ADSK, TEAM, SNOW, EA, TTWO, NET, VEEV, RBLX, XYZ, and DDOGShould you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include Autodesk (ADSK), Atlassian (TEAM), Snowflake (SNOW), Electronic Arts (EA), Take-Two Interactive Software (TTWO), Cloudflare (NET), Veeva Systems (VEEV), Roblox (RBLX), Block (XYZ), and Datadog (DDOG). These companies are all part of the "prepackaged software" industry. Genesis Healthcare vs. Autodesk Atlassian Snowflake Electronic Arts Take-Two Interactive Software Cloudflare Veeva Systems Roblox Block Datadog Autodesk (NASDAQ:ADSK) and Genesis Healthcare (NYSE:GEN) are both large-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk. Does the media prefer ADSK or GEN? In the previous week, Autodesk had 56 more articles in the media than Genesis Healthcare. MarketBeat recorded 56 mentions for Autodesk and 0 mentions for Genesis Healthcare. Autodesk's average media sentiment score of 0.46 beat Genesis Healthcare's score of 0.00 indicating that Autodesk is being referred to more favorably in the media. Company Overall Sentiment Autodesk Neutral Genesis Healthcare Neutral Which has more risk & volatility, ADSK or GEN? Autodesk has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Is ADSK or GEN more profitable? Autodesk has a net margin of 18.30% compared to Genesis Healthcare's net margin of 17.83%. Genesis Healthcare's return on equity of 155.48% beat Autodesk's return on equity.Company Net Margins Return on Equity Return on Assets Autodesk18.30% 53.87% 12.31% Genesis Healthcare 17.83%155.48%9.12% Does the MarketBeat Community favor ADSK or GEN? Autodesk received 795 more outperform votes than Genesis Healthcare when rated by MarketBeat users. Likewise, 69.40% of users gave Autodesk an outperform vote while only 65.43% of users gave Genesis Healthcare an outperform vote. CompanyUnderperformOutperformAutodeskOutperform Votes127069.40% Underperform Votes56030.60% Genesis HealthcareOutperform Votes47565.43% Underperform Votes25134.57% Do insiders and institutionals have more ownership in ADSK or GEN? 90.2% of Autodesk shares are owned by institutional investors. Comparatively, 82.1% of Genesis Healthcare shares are owned by institutional investors. 0.1% of Autodesk shares are owned by company insiders. Comparatively, 3.3% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate ADSK or GEN? Autodesk presently has a consensus target price of $321.59, suggesting a potential upside of 23.94%. Genesis Healthcare has a consensus target price of $31.50, suggesting a potential upside of 28.83%. Given Genesis Healthcare's higher possible upside, analysts plainly believe Genesis Healthcare is more favorable than Autodesk.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autodesk 0 Sell rating(s) 8 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.65Genesis Healthcare 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation and earnings, ADSK or GEN? Autodesk has higher revenue and earnings than Genesis Healthcare. Genesis Healthcare is trading at a lower price-to-earnings ratio than Autodesk, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutodesk$6.13B9.01$906M$5.1350.58Genesis Healthcare$2.80B5.59$836M$0.9027.17 SummaryAutodesk beats Genesis Healthcare on 15 of the 18 factors compared between the two stocks. Get Genesis Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEN vs. The Competition Export to ExcelMetricGenesis HealthcarePrepackaged software IndustryBusiness SectorNYSE ExchangeMarket Cap$15.63B$21.94B$7.01B$18.42BDividend Yield3.05%1.95%2.68%4.17%P/E Ratio27.17105.0429.4931.09Price / Sales5.5916.63163.3726.53Price / Cash8.4286.0631.6117.52Price / Book-152.817.784.544.30Net Income$836M$438.39M$195.94M$1.02B Genesis Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GENGenesis Healthcare2.3293 of 5 stars$24.45+0.6%$31.50+28.8%+19.3%$15.63B$2.80B27.172,700ADSKAutodesk4.4354 of 5 stars$260.71+0.9%$326.91+25.4%+19.8%$55.53B$6.13B51.7312,600Analyst ForecastAnalyst RevisionNews CoverageTEAMAtlassian4.4884 of 5 stars$200.99+1.3%$300.00+49.3%+5.8%$52.66B$4.79B-149.998,810Analyst ForecastInsider TradeGap UpSNOWSnowflake4.6072 of 5 stars$144.34-0.4%$202.51+40.3%-1.5%$47.65B$3.63B-42.583,990Analyst ForecastAnalyst RevisionNews CoverageEAElectronic Arts4.2906 of 5 stars$145.50+1.8%$155.30+6.7%+14.4%$37.92B$7.35B37.0212,900Analyst ForecastInsider TradeShort Interest ↓News CoverageTTWOTake-Two Interactive Software3.5667 of 5 stars$212.95+0.4%$213.38+0.2%+51.3%$37.58B$5.45B-9.987,800Analyst ForecastNews CoverageNETCloudflare4.7507 of 5 stars$106.84+0.6%$134.88+26.2%+28.2%$36.87B$1.67B-485.643,220Analyst UpgradeInsider TradeShort Interest ↓News CoveragePositive NewsGap UpVEEVVeeva Systems4.0709 of 5 stars$223.91+2.7%$256.52+14.6%+8.8%$36.43B$2.75B55.295,480Analyst ForecastInsider TradeNews CoveragePositive NewsRBLXRoblox2.8457 of 5 stars$56.96-0.5%$64.22+12.7%+69.2%$35.99B$3.60B-39.282,130Analyst ForecastGap UpXYZBlock4.5768 of 5 stars$54.71+1.4%$91.52+67.3%N/A$33.89B$24.12B12.0212,985Analyst ForecastAnalyst RevisionNews CoverageDDOGDatadog4.8341 of 5 stars$91.88-0.2%$154.81+68.5%-24.2%$31.49B$2.68B180.164,800Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies ADSK Alternatives TEAM Alternatives SNOW Alternatives EA Alternatives TTWO Alternatives NET Alternatives VEEV Alternatives RBLX Alternatives XYZ Alternatives DDOG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GEN) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genesis Healthcare, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genesis Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
